header logo image


Page 774«..1020..773774775776..780790..»

10 Habits to Create Less Stress in Your Daily Life (Part 2) – Thrive Global

December 29th, 2019 12:49 pm

Dr. Bojana Jankovic Weatherly is an award-winning physician, double board certified in internal and integrative medicine. After completing internal medicine residency, she did a fellowship in integrative medicine trained in functional medicine, nutrition and mindfulness. Her approach is rooted in evidence-based medicine that is personalized to each individual she works with. She partners with her patients to discover and address the root causes of their conditions and develops individualized plans to support and empower each unique individual to achieve her or his health goals. As part of her mission to deliver accessible, evidence-based health and wellness information, she created her website, drbojana.com, that features her videos, articles and recipes.

Dr. Bojana is the recipient of several patient satisfaction awards at Cedars-Sinai and was recognized as the Southern California Top Doctors Rising Star in 2016 and 2017 and awarded the Top Doctor recognition in 2018 and 2019 in New York.

Prior to starting her integrative and functional medicine practice, she worked as a primary care physician at Cedars-Sinai Medical Group and Crossover Health,providedexecutive healthcare at EHE and worked at Dr. Frank Lipmans Eleven Eleven Wellness.She was the Co-Founder of and served as the Chief Medical Officer of WellStart Health, a digital therapeutics start up for chronic disease prevention and reversal. She currently serves as their Medical Advisor.

A lifelong learner, she completed a fellowship in Integrative Medicine established by Dr. Andrew Weil at the University of Arizona and continues to train in functional medicine at The Institute for Functional Medicine. She completed her Internal Medicine residency at Cedars-Sinai Medical Center and West LA Veterans Affairs in Los Angeles. She completed medical school, Master of Science (Experimental medicine) and Bachelor of Science (Biophysics Honors) degrees at University of British Columbia in Vancouver, Canada. Throughout her academic career, Dr. Bojana Jankovic Weatherly performed research in endocrinology and oncology, published papers in peer-reviewed journals and presented her work at academic conferences. She is the recipient of numerous honors and awards. She has also established herself as an educator and speaker, teaching medical students and residents, and speaking on health and wellness in academic and corporate settings, podcasts, and wellness events. She has also shared her medical expertise on Today Show and Rachael Ray.

In addition to serving on the Board of EWG, she serves on the Board of Directors and has been honored for her contribution by Lifeline New York, a nonprofit organization that provides support to Serbian hospitals and children in need, and is on the Board of Tryall Fund, a non-profit organization that promotes health and education in Jamaica.

Dr. Bojana loves spending time with her two children and husband in nature, experimenting in the kitchen, doing ballet barre and practicing mindfulness and yoga. Her not guilty pleasure: Reishi mushroom coffee in the morning. Guilty pleasure: anything with chocolate.

Dr. Bojana Jankovic Weatherly practices at 245 5th Avenue, 3rd Floor, NY, NY 10016.

Go here to see the original:
10 Habits to Create Less Stress in Your Daily Life (Part 2) - Thrive Global

Read More...

How to Take Charge of Your Migraines – Thrive Global

December 29th, 2019 12:49 pm

Lets first talk about what migraines are. Migraine is a type of headache that can be quite disabling and can last from hours to several days. It is typically associated with nausea and vomiting, light and/or sound sensitivity, and tends to be characterized by throbbing pain on one side of the scalp. Other features may include vision disturbances, numbness or weakness of one part of the body or even vertigo. Migraines can occur several times per week, or once or twice per year.

Migraine headaches affect 12% of the US population and are up to3 times more common in women than in men(up to 6% of men and up to 17% of women have them. Theprevalence of migraines increases up until the age of 39. In a group of women aged 30-39, close to 1 in 4 may have a migraine.

Mechanisms leading to migraines are complex and not fully understood. Scientists believe that migraines result from a malfunction of neurons (nerve cells) that leads to a sequence of changes that lead to migraine symptoms described above. Both genetic and environmental factors are involved in migraines.

When it comes to migraine headaches, there are 2 basic approaches in conventional medicine when it comes to treating the symptoms.

A class of drugs known as triptans (e.g., sumatriptan (Imitrex), rizatriptan (Maxalt), or naratriptan (Amerge)), may be used to abort the symptoms once they start. Non-steroidal anti- inflammatory medications such as ibuprofen (Advil) or naproxen (Aleve) may also be used.

Those who have frequent migraines may be on medications for migraine prevention, or even have Botox to help prevent migraines. Some of the oral medications that help prevent migraines include anti-seizure medications such as topiramate (Topamax), beta-blocker medications such as propranolol (Inderal), and anti-depressants such as amitriptyline (Elavil). In 2018, the FDA approved drugs that are calcitonin gene-related peptide (CGRP) antagonists for migraine prevention. More data are needed to know the long term safety of these medications.

While it is important to get migraine symptoms under control, it is just as important to understand the root cause of migraines and identify any possible triggers. Many of my patients migraines are triggered by certain foods, by skipping meals or by alcohol.

Many of my patients find that their migraine frequency increases when they dont sleep well and their stress levels are high. Working with your qualified healthcare practitioner is key in both adequately addressing your symptoms but also identifying triggers, so that you reduce these symptoms and their frequency, or even completely eliminate them.

Prevention is key. Although it may take considerable detective work to understand what triggers your migraines, it is generally easier to prevent a migraine than it is to have to endure the symptoms and treat it.

Here are my top tips:

Here is a list of supplements you may want to ask your provider about, that can help reduce the frequency of migraines:

*Sublingual ginger and feverfew have been found torelieve migraine attacks.

None of the information in this article is a representation or warranty that any particular drug or treatment is safe, appropriate or effective for you, or that any particular healthcare provider is appropriate for you. Never disregard professional medical advice or delay seeking help from a health care provider due to something you have read or seen in this article. Your reading/use of this article does not create in any way a physician-patient relationship, any sort of confidential, fiduciary or professional relationship, or any other special relationship that would give rise to any duties. This article does not recommend or endorse any specific tests, healthcare providers, procedures, or treatments, and if you rely on any of the information provided by this article, you do so solely at your own risk.

More here:
How to Take Charge of Your Migraines - Thrive Global

Read More...

The Kensington hotel hits the heights with the finest of London luxury – Yorkshire Post

December 29th, 2019 12:49 pm

South Kensington is the best of tourist London, condensed - great culture, brilliant food and characterful shops, all within walking distance.

But where to stay? One hotel puts itself front and centre of the pack.

The Kensington, housed in a magnificent white stuccoed building on Queen's Gate, a street lined with equally grand properties, is a five-star venue that - in a city with some extremely stiff competition - does luxury very well indeed.

Part of the Doyle Collection group, the place blends modern sleekness with Victorian splendour. The 150-room hotel is made up of four 19th century townhouses, mixing high-ceilinged spaciousness with a certain intimacy, aided by crackling open fires and a surfeit of comfortable armchairs in the lounge.

South Kensington tube station is just 10 minutes away on foot - the stop is easily reached from the major London stations. Our journey was a pleasant, brisk two hours to Euston from Manchester Piccadilly with Virgin Trains, which has now handed over to Avanti West Coast following a franchise change.

If our trip was anything to go by, it's definitely worth upgrading to First Class as a treat - the quiet carriage, complimentary food, comfortable seats and relaxing passenger lounges were everything train travel should be.

The Kensington has a couple of special touches, one of which is its on-site juicery - according to the literature, leaders in 'nutrition, health, fitness, beauty and integrative medicine' were commissioned to come up with recipes for restorative drinks. Accordingly, while checking in we were served two glasses of a concoction called London Greens - a blend of pear, spinach, cucumber, basil, lime and coconut water, which certainly achieved the stated aim of 'recovery and rehydration'.

The staff were overwhelmingly helpful - from collecting, storing and carrying bags to supplying recommendations and fetching bottles of mineral water from a seemingly endless supply. The Kensington is such a well-oiled machine that a brief shortage of cereal bowls at breakfast, where every morning whim is catered for, generated the atmosphere of a small crisis.

Our studio suite - a generously-proportioned space with shuttered windows leading to a small balcony, where The Kensington's flag fluttered over Queen's Gate - blended classic English decadence and Far East exoticism, enlivened with a smattering of eclectic artworks. The bathroom had classy Malin + Goetz toiletries and an enormous freestanding roll-top tub as its centrepiece, as if to challenge anyone not to turn on its gold taps for a long soak immediately.

The streets around The Kensington are blessed with some fine restaurants, so the hotel has stepped up to the mark with its own venue, Town House. The clientele is a mix of guests and diners who aren't staying the night, which at a hotel is always an encouraging sign - the atmosphere is relaxed, well-stocked bookshelves line the walls and, next door, the oak-panelled K Bar is the ideal spot for an aperitif before taking a table.

Executive chef Adi Mandokhot's a la carte menu caters for all tastes, in the best sense. Starters of tiger prawns, harissa aioli and lime, and Dorset crab on toast with watercress and apple, were thoughtful combinations of saltiness and sharp fruits, while mains of heritage rib eye steak from the Josper Grill were deeply satisfying, unashamedly marbled with fat, delivering bold flavours and served with a superbly buttery Barnaise sauce.

Desserts maintained the quality - a burnished apple tart tatin and a decadent chocolate bombe are some of the delights on offer.

The Kensington shares its Victorian heritage with the V&A, a short distance away from the hotel on foot. Simply one of the world's greatest museums dedicated to art and design, nobody need worry if they haven't bought a ticket to one of the blockbuster exhibitions - there are enough outstanding artefacts, from fashion to metalwork and beyond, to occupy anyone for days.

The Design Museum - easily reached via the tube to Kensington High Street - is a must as well, attracting its own sell-out shows such as the recent survey of director Stanley Kubrick's archives that wowed visitors with props and costumes from 2001: A Space Odyssey, A Clockwork Orange and the rest of the cinema pioneer's canon.

Kensington might just have the recipe for a perfect weekend.

The Kensington, 109-113 Queen's Gate, South Kensington, London, SW7 5LP. Rooms from 290 per night, call 020 7589 6300 or visit http://www.doylecollection.com/hotels/the-kensington-hotel to book. Direct rail services to London Euston from Manchester Piccadilly run from early until late every weekday and at weekends, with full breakfasts, brunch, lunch and evening meals available for first class passengers. See http://www.avantiwestcoast.co.uk for times or to book tickets.

Go here to see the original:
The Kensington hotel hits the heights with the finest of London luxury - Yorkshire Post

Read More...

Extinction Rebellion is using holacracy to scale its international movement – Quartz

December 29th, 2019 12:49 pm

One of the defining events of 2019 was Extinction Rebellion, the global protest movement bolstered by activists like Greta Thunberg to make the climate emergency a priority for governments around the world.

Since its founding in 2018, XR, as its known, has mobilized thousands of people in dozens of countries, brought sections of London, New York, and Sydney to a standstill, and spawned 3,000 arrests in the UK alone (purposeful arrests are a core part of its strategy).

While the movement has received its share of criticism as it has grown in size and powernamely around its lack of diversityits sheer numbers and degree of international press coverage point to an enviable level of operational success.

A key to this success? Choosing an effective organizational model early on, informed by the latest management science. XR is a decentralized network designed to resemble a holacracy, an operating structure for self-organization tested by tech companies like Google, Zappos, and Medium. Anyone can join XR so long as they adhere to its 10 core principles and values, including a commitment to nonviolence.

While holacracy, too, has received its share of criticism as it, too, has gained traction, the system is credited for providing a basic framework for effective self-organization. At a holacracy training session at Zappos, the online shoe retailer, in 2013, HolacracyOne co-founder Brian Robertson, who invented the system, described his creation as providing a rule system for anarchy.

Extinction Rebellions embrace of holacracy makes it the largest-scale use case to date, eclipsing Amazon-owned Zapposs high-profile trials with holacracy involving 1,500 employees. Like Zappos, which has quietly backed away from certain tenants of the system and has begun to experiment with its own, modified version of holacracy, XR is also taking a broader interpretation of holacracy.

Were not dogmatic about using holacracy; its an adaptive version, says Ronan Harrington, a UK political strategist who was personally recruited by XR co-founder Roger Hallam to join the movement.

XR is not formally engaging HolacracyOnes services. Instead, its leadership has trained itself using online videos and with guidance from advisors like Miki Kashtan, an international teacher of nonviolent communication and former McKinsey consultant Frederic Laloux, whose internationally bestselling book Reinventing Organizations profiles successful self-managed organizations, including HolacracyOne.

The defining feature of a holacracy is its circular hierarchical structure, which is quite different from the static pyramid hierarchies most organizations employ today. The flattened hierarchy, combined with a focus on granular roles over broader job titles, as well as distributed decision-making and clear frameworks for conflict resolution, makes holacracy a more dynamic and scalable option for self-organizing entities like XR.

Reflecting basic holacratic structure, XR has a number of core circles that focus on everything from finance and fundraising to legal, tech, and even the nature of self-organizing systems. The core circles send representatives to the main circle, led by XR co-founders Hallam and Gail Bradbrook. Feedback loops run quickly both down- and upstream. Those in core roles are empowered to make decisions as they see fit, so long as they consult with others who have expertise in order to make thoughtful decisions.

More complex decisions involve integrative decision making, a process where all proposals need to pass with no objection. When necessary, a rapid-response team makes faster decisions on strategy and other issues.

The movement has learned from the mistakes of Occupy Wall Street, which was weighed down by crowded general assemblies that made decisions by consensus, which quickly became a hindrance to progress. By contrast, holacracy is designed to protect against that kind of gridlock by empowering individuals to act with full sovereignty within the scope of their roles, while retaining a democratic bent through its governance and integrated decision-making processes.

Harrington notes that the average XR protester probably would not even know that they are operating within a holacracy (though the group does hold training sessions on holacracy in various local chapters). People know [holacracy] by the processes we have, he explains. For most people its their first experience in a self-organizing system.

Daniel Thorson, who has explored the concept of societal and ecological collapse through his podcast Emerge: Making Sense of Whats Next, participated in the UK protests this past autumn. While he wasnt initially aware of XRs holacratic design, he observed that anyone was empowered to act as they desired, so long as it was in accordance with the movements principles. He kept up-to-date on the campaigns UK strategy through a widely broadcast channel on Telegram, the encrypted messaging service. Transparent information flow is a core tenet of holacracy because it fosters trust, the lynchpin of all effective self-organized systems.

Thorson, who also participated in Occupy Wall Street, was struck by the way XR participants were noticeably more in control of their emotions than the Occupiers were, evidenced by a more cool-headed approach to protesting.

In Londons Trafalgar Square, youd come across a sign for therapeutic yoga and sound healing, right next to a table for the scientists of XR, and the Buddhists of XR, he said, referring to the mixture of the spiritual and the sacred within the context of the protest movement. At Occupy there would have been antipathy for that.

On Thorsons podcast following his visit to the UK, he interviewed Harrington, who pointed out that many XR protesters have done their shadow work, that is, healed traumas within themselves so they dont project dysfunctional conditioning onto others, namely law enforcement.

They have done inner work on antagonism, so they are projecting less onto the public, explained Harrington, noting the clear link between self-development and systems transformation. [When] an activist hasnt actually processed the rage and the anger that comes from issues with their mothers and fathers, they project that onto the system. And people feel that.

Thorson adds that the inherent discomfort associated with protesting can easily trigger unhealed emotional wounds. You can tell where trauma is if you get irritated, he says. There are so many opportunities for people to freak out. People were more angry and rageful at Occupy, whereas at XR people are pretty peaceful. Its more of a festival atmosphere.

The XR movement itself has its roots in the spiritual. In 2016, Bradbrook attended an ayahuasca ceremony in Costa Rica for activists with the intention of discerning the codes for social change. (Ayahuasca is a plant-based medicine thought to have a mind-opening effect.)

Not long after, Bradbrook, a former biophysicist, met Hallam, a former organic farmer who is pursuing a PhD at Kings College London centered on how to create social change; and together they began laying the groundwork for XR. The activists studied notable protest movements in modern history and determined that nonviolence, promoted by the likes of Gandhi and Martin Luther King Jr., has by far been the most effective strategy. Their message was bolstered by the work of Jem Bendell, a professor of sustainability leadership at the University of Cumbria, who published a viral academic paper in July 2018 discussing the need for deep adaptation in the face of impending ecological collapse.

Using holacracy as an operating system, they scaled XR globally in relatively fast order, starting with the groups official founding in October 2018 and accelerating with mass protests in April and October of this year. The campaign has brought attention to the climate emergency, but it is still far from persuading political leaders to meet its demands, which include a commitment by the British government to reach net-zero greenhouse gas emissions by 2025. Based on their academic research, XRs leaders predict it will take 3.5% of the population getting involved to affect systemic change.

As XR strategizes for its next phase in 2020, it is also integrating lessons Hong Kongs pro-democracy movement, which is leaderless out of necessity. We admire their Bruce Lee, be-like-water approach, says Harrington, though he is quick to note a core difference between the two is XRs commitment to non-violence. Either way, he says, Hong Kong shows us the value of keeping something in the news long enough.

Original post:
Extinction Rebellion is using holacracy to scale its international movement - Quartz

Read More...

The Art of the Yoga Practice – Jewish Link of New Jersey

December 29th, 2019 12:49 pm

Stressful news comes in all shapes and sizes. For some it is sudden news of financial struggle, and for others it comes in the form of being laid off from a job. In this weeks parsha we read how Yaacov dealt with his own stressful news.

The defining moment had come. The brothers had to tell their father, Yaakov, that Joseph was alive. There was arguing amongst themselves as to how to deliver this news. For all these years, Yaakov believed his favorite son, Joseph, was dead. To bring out these facts now, including the background story, could have such an impact on Yaakov that the brothers feared it would kill him upon hearing the news.

A genius solution appeared. Yaakovs cherished granddaughter, Serach, would be brought in. She would sing the story of what happened to Joseph through her beautiful, comforting voice. Serachs song would tell the tale of Josephs sale into slavery and how he came to be alive. Her lovely voice would create a soft arrow that would go from the story of Josephs life and travel into the tender interior of Yaakovs heart, allowing Yaakovs body to remain alive as he took in this jarring news.

I know I have invented my own methods for slowing down the impact of difficult news. When I opened my email to read the feedback forms (criticism) from the womens yoga retreat I ran at Isabella Freedman Retreat Center, I covered my eyes and read the reviews through the cracks of light in between my fingers, stockading myself for the worst. If I started to read something really upsetting, I could close my fingers tight and block the view. Ninety-nine percent of the feedback forms came back outstanding; the crowd raved! But there was that one voice, ok, maybe several voices, that said I talked too much, as well as some other points of criticism that made me feel glad I was reading them through the cracks of light through my fingers.

I have a low threshold for criticism. Still, I have gotten better through the years, and I attribute my growing ability to tolerate uncomfortable feelings to the consistent physical practice of yoga and breathing. Yes, breathing! Intentional deep diaphragm breathing lowers cortisol stress hormones and supports the neocortex part of the brain to make logical decisions during times of stress.

Not long ago, my 92-year-old mother (thank God) spent a day preparing for an unpleasant minor procedure to be done the following day. By the time she arrived for the procedure, she was all riled up, and her blood pressure was way too high to move ahead. My mother told the doctor that she was not going home until the procedure was done, no matter what. So, they brought in a nurse to breath with her in an attempt to lower her blood pressure enough to complete the procedure. My determined mother became focused and quiet, taking deep rhythmic breaths with the nurse. As her breathing slowed, she moved out of her fight-or-flight state and into a state of calm. Within the hour, her blood pressure was rechecked, and this time the anesthesiologist felt safe enough to move ahead with the procedure.

Worrying about a single event coming up, as with my mother, is one thing. But we can find ourselves in an ongoing, constant state of fight or flight, not even being aware of it. This is all thanks to stress hormones. These horomones naturally lower by nighttime, but if we are living day-to-day as if there might be a disaster ready to happen at any moment, a high rate of stress hormones will circulate and wont slow down enough to get a good nights sleep. This, we do not want.

Practicing the yoga poses and breathing deeply in an intentional way is a simple yet powerful tool for creating positive changes in our physiology, all while supporting our nervous system in an effort to calm down. Through the physical practice of yoga, blood pressure rates lower. Muscle tensions are released. Cortisol stress hormone rates come down. Heart rate variability increases, as does the release of serotonin in the brain, which naturally creates a sense of well-being.

There are specialists whose disciplines tackle these issues: Dr. Nancy Lentine has a private practice in integrative family medicine, specializing in the endocrine hormone system. Stephen Cope is the founder and director of the Kripalu Institute for Extraordinary livinga research institute that examines the effects and mechanisms of yoga and meditation.

With tools to calm our physical body, there is more ability to tolerate the difficult emotions and feelings that will come in our life experiences and memories. In the story of Yaakov, the news was told to him slowly and sweetly. He was able to keep breathing, sustaining his own life. His intellect had a chance to process the shocking story of his son and he was able to contain and hold the strong feelings, setting himself up for success.

Whether you are new to the practice of yoga or a seasoned practitioner, now is the time to check out the yoga and meditation classes at Freedom Within Yoga Studio in Teaneck. For more information call 201-920-7408 or go to http://www.freedomwithinyoga.com.

Read the original here:
The Art of the Yoga Practice - Jewish Link of New Jersey

Read More...

This Is How Human Head Transplants Could Be Achieved, According To A Neurosurgeon – IFLScience

December 29th, 2019 12:48 pm

The idea of transplanting a human head onto another persons body may sound like the stuff of science fiction and thats because it is. But while penning a fictional story about the worlds first cranial exchange, neuroscientist Bruce Mathew came up with an idea that he says could soon become a real-life procedure.

Speaking to The Telegraph, Mathew who was previously the clinical lead for neurosurgery at Hull University Teaching Hospitals NHS Trust explained that a head could be grafted onto another body if the entire spinal cord is transplanted along with it.

Initially our intention was to just brainstorm an idea and it seemed rather silly, but then I realized, it actually isnt. If you transplant the brain and keep the brain and spinal cord together its actually not impossible, he said.

The spinal cord is the most profound thing imaginable. You need to keep the brain connected to the spinal cord. The idea that you cut the spinal cord is utterly ridiculous."

Obviously this is not an easy thing to do, and while recent advances have opened up the possibility of reattaching individual severed nerves, the prospect of connecting an entire spinal column is still some way out of reach.

Yet with surgical technologies improving at a rapid rate, Mathew says it is not entirely unrealistic to think that it will probably happen in the next 10 years.

At the moment, you can connect one or two nerves, but with robotics and artificial intelligence well soon be able to do 200 nerves, he explained.

Of course, there are likely to be many complications with such a procedure, as the recipients body will probably reject such a large amount of donor material. While Mathew hasnt figured out all the solutions in detail, he says that transferring gut bacteria along with the head and spinal cord, and stem cell transplants, may help to ensure that the transplant is accepted.

At present, Mathew has no plans to take his idea any further than the pages of his science fiction novel, although Italian neurosurgeon Sergio Canavero has spent the last few years actively attempting to achieve a human head transplant.

In 2017 he announced that he had successfully transplanted the head of one human corpse onto another, and previously claimed to have grafted a donor head onto a monkey although the animal never regained consciousness and would probably have been paralyzed if it had, as the spinal cord remained unattached.

Despite this, Canavero apparently has a willing human donor, and of course, there are thousands of people (and sometimes just heads) across the world cryonically frozenin the hope medicine and technology of the future will be able to revive them. Perhaps it will happen one day, but we're not quite there yet.

Read more here:
This Is How Human Head Transplants Could Be Achieved, According To A Neurosurgeon - IFLScience

Read More...

Transplanting human heads on to another body possible by 2030 – Samaa News

December 29th, 2019 12:48 pm

A former neurosurgeon, who worked with the UKs National Health Service, has a surprising prediction for the next decade. He claims human head transplants will become a reality by 2030.

Dr Bruce Matthew said this during an interview with The Telegraph on December 21. He says the revelation came to him while he was working on a science-fiction novel with futurist author Michal J Lee.

Ifyou transplant the brain and keep the brain and spinal cord together itsactually not impossible. The spinal cord is the most profound thing imaginable.You need to keep the brain connected to the spinal cord. The idea that you cut the spinal cord isutterly ridiculous, he told The Telegraph.

Previous(unsuccessful) attempts at the controversial procedure focused on severing thespinal cord from the brain and then transplanting the head after connectingnerves, blood vessels and meninges (the covering of the brain and spinal cord).

This happened in2017 on a human corpse. Controversial Italian neurosurgeon Dr Sergio Canavero and DrXiaoping Ren of Harbin Medical University, China carried out the 18-hour procedurewhich was later slammed by scientists and bioethicists the world over.

Dr Matthew admits that the future process will be tricky because shifting the spinal cord intact is impossible.

It will take a number of advancements and incremental steps but it will probably happen in the next 10 years, said the former surgeon, who was a clinical lead for neurosurgery at Hull University Teaching Hospitals NHS Trust in the UK and has 25 years of experience.

Hesays the feat will be accomplished with the help of cryogenics (freezing deadbodies in nitrogen), robotics, stem cell therapy and artificial intelligence.

Who will head transplants help?

People with terminal illnesses whose brains are still intact, those with neurodegenerative muscle diseases, the rich who have already frozen their bodies it costs somewhere between $28,000 and $200,000 in hopes of reincarnation.

Basically,those with an intact brain.

Why are head transplants so controversial?

Apartfrom the medical limitations and lack of scientific research on the topic, thebiggest issue that arises is an ethical one.

Doesthe person remain the same person? Will identity also be transferred? DrMatthew says shifting the spinal cord means shifting a persons consciousness. Asfor DNA, hes proposed shifting stem cells from the patient to the donors bodyso a new colony of original DNA can be built.

Scientists also say the donor body runs the risk of being paralysed because of the procedure. Bioethicists say the surgery will have profound psychological, legal and moral complications.

Follow SAMAA English onFacebook,Twitter,andInstagram.

See more here:
Transplanting human heads on to another body possible by 2030 - Samaa News

Read More...

Autologous Stem Cell and Non Stem Cell Based Therapies Market to Garner Brimming Revenues by 2023 – Industry Mirror

December 29th, 2019 12:48 pm

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

To obtain all-inclusive information on forecast analysis of Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Request a PDF Brochure Here https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

This post was originally published on Industry Mirror

Visit link:
Autologous Stem Cell and Non Stem Cell Based Therapies Market to Garner Brimming Revenues by 2023 - Industry Mirror

Read More...

Heard on the Street: Nominate your favorite local businesses – Kankakee Daily Journal

December 29th, 2019 12:47 pm

Honor your favorite local businesses by nominating them in the first-ever Daily Journal Readers Choice Awards.

The public is invited to nominate their favorite local businesses in categories such as children and education, dining, entertainment, health and beauty, home services, places, shopping and vehicle dealer and services.

Once the nomination period ends, the public is again invited to vote for their favorite in each of the categories, Jan. 15 through Jan. 28.

Winners in each category will be announced and featured in the Daily Journal in February.

Olivet Nazarene University recently reimagined and revamped the Department of Computer Science and Emerging Technologies, formerly known as the Department of Computer Science.

Based on the advice of industry leaders, the Council of Software Programmers and the Universitys CSET Advisory Council, the Walker School of Engineering and Technology decided to modify requirements, expand course concentrations and add more certification options.

Changes to the curriculum and degree requirements will go into effect for the fall 2020 semester.

The program changes also will incorporate the universitys cybersecurity lab, housed in Reed Hall of Science.

Olivets department of CSET is an Amazon AWS Academy offering courses in cloud foundations, cloud architecture and cloud development. Students can pursue certifications in CompTIA Network+, CompTIA Security+, CompTIA Server+, CompTIA Linux+, AWS-CDA, AWS-CP, AWS-CSA, EC-CIH and EC-CEH and will become familiar with Python, Java, PHP, C and Assembly languages.

ONU offers three degrees in the department, a bachelor of arts degree in computing technology, a bachelor of science degree in computer science and emerging technologies and a bachelor of science degree in cybersecurity.

OAK Orthopedics, with offices in Bradley, Frankfort, New Lenox and Watseka, now offers diagnostic imaging and minimally invasive surgery using NanoScope by Arthrex.

This surgical technology, nano arthroscopy, an even less invasive form of arthroscopy, uses a small camera to find and repair joint problems.

For decades, arthroscopy has provided patients with a minimally invasive joint repair treatment option. Now, nano arthroscopy offers the next step in efficient and precision care for joint injuries and conditions.

The NanoScope is even smaller and more flexible than traditional arthroscopes, and OAK Orthopedics use it as a diagnostic tool with alternative views and a treatment tool.

This technology is going to optimize what we can do for our patients, said fellowship trained sports medicine surgeon Dr. Michael Corcoran of OAK Orthopedics. From navigating a tight or curved joint area to being able to access areas that are difficult to visualize even with an MRI, the NanoScope allows surgeons to see and treat problems in a more efficient way.

See more here:
Heard on the Street: Nominate your favorite local businesses - Kankakee Daily Journal

Read More...

Vaccinations in California Rebound Less Than 5 Years After SB 277 According to New Study – California Globe

December 29th, 2019 12:47 pm

Less than 5 years after SB 277 was signed into law and removed personal belief vaccination exemptions for children in public schools, the number of vaccinated children in California has skyrocketed.

A recently released study in the the medical journal PLOS Medicine has found that measles, mumps, and rubella vaccines have seen a 3.3% increase in California, a similar declination of exemptions, and no major outbreak of diseases like the measles since the Disneyland case in 2014 the very incident that sparked passage of SB 277.

Vaccination rates have also shot up from 92.8% in 2015 to 95% in 2017.

Child vaccinations also saw the largest climb in high-risk counties, where vaccination rates went up nearly 10%.

This is really good news for California, said Dr. Richard Nguyen, a pediatrician. There had been an uptick of parents refusing to vaccinate their kids for all sorts of reasons, but now its getting back to normal.

Less kids are getting sick, and Ive actually been getting apologies from parents who had formerly cursed me out over having to be forced to vaccinate their kids because they believed the myth that they can cause autism or weaken them in some way. I actually got a voicemail last week from a mother of a child I do checkups on who said she was sorry for not believing me and other doctors after her daughter had a recent measles scare.

Recently passed laws such as the hotly contested SB 276, which cut back on the number of medical exemptions and now allows investigations on doctors who write more than 5 medical exemptions a year, also show that California lawmakers and citizens are gradually moving away from anti-vaccination beliefs.

A large reason for the growth is that its now almost forced, said John Graves, a policy expert in Los Angeles. Parents arent given the choice anymore. The vast majority of parents believe in vaccines and want them for their own children because they dont want an outbreak or to spread debilitating diseases. So parents who want to opt out are ostracized.

From the cases Ive seen, other parents understand if its for a religious purpose or because theres a medical reason like an allergy or something to the vaccine. Theyll just be more careful around the children who dont have vaccines. But nearly all parents cant stand those that dont want to do it for the hell of it, or if theyre misguided.

This is a health and wellness issue, and it always has been. If its not for a legitimate reason, most parents think the person who doesnt vaccinate doesnt love their child. Ive seen a lot of similarities between this and in the 70s and 80s when seat-belt buckling for children became a huge issue, when there were claims that the seat belts hurt their kids more than helped them.

But now were seeing the tide turn with those new studies. It just took a lot of time for some parents to start getting it.

Evan V. Symon is the Senior Editor for the California Globe. Prior to the Globe, he reported for the Pasadena Independent, the Cleveland Plain Dealer, and was head of the Personal Experiences section at Cracked. He can be reached at evan@californiaglobe.com.

Continue reading here:
Vaccinations in California Rebound Less Than 5 Years After SB 277 According to New Study - California Globe

Read More...

Stoke Therapeutics Added to NASDAQ Biotechnology Index – Business Wire

December 28th, 2019 9:51 am

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). This addition is effective prior to market open today.

The NASDAQ Biotechnology Index tracks the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Selected companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Stoke TherapeuticsStoke Therapeutics, Inc. (Nasdaq:STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The companys lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Excerpt from:
Stoke Therapeutics Added to NASDAQ Biotechnology Index - Business Wire

Read More...

Biotechnology Based Chemicals Market Key Players, Industry Overview and Forecast Analysis by 2020 – Market Research Sheets

December 28th, 2019 9:51 am

Biotechnology is a technological application that uses living organisms, biological systems or derivatives to produce or modify products or processes for specific use. Biotechnology encompasses a wide range of procedures required for modifying living organisms to fulfill various demands for domestic as well as industrial applications. Thus, biotechnology is a general term that is used for a wide range of techniques that are involved in the production, transformation or degradation of the desired product. Biotechnology based chemicals are the products that are manufactured by applying various techniques such as fermentation. Biotechnology based chemicals comprises polyhydroxyalkanoates, lactic acid, lysine, citric acid, glutamic acid and threonine. The technology used in manufacturing biotechnology based chemicals are simple however, the entire production process should be carried out under the supervision of trained personnel. Glutamic acid is the most widely used amino acid manufactured as well as consumed in the world. Biotechnology based chemicals find application in pharmaceuticals, food industry, animal feed and consumer goods manufacturing industries among others.

Pharmaceutical industry is the largest consumer of biotechnology based chemicals. The growing demand for natural medicines than that compared to synthetic chemicals is expected to augment the overall demand for biotechnology based chemicals. In addition, growing awareness of the several side effects associated with the chemical drugs is expected to boost the overall biotechnology based chemicals market. The animal feed industry is also one of the major consumers of biotechnology based chemicals market. The growing demand for lysine in animal feed is expected to boost the overall demand for biotechnology chemicals market. Lactic acid finds applications in a wide range of industries. The growing demand for manufacturing polylactic acid (PLA) plastics boost the demand for lactic acid which in turn is expected to augment the overall biotechnology based chemicals market. However, high cost associated with the manufacturing of biotechnology based chemicals is expected to restrain the overall growth of the market.

The growing demand for pharmaceutical products has expected to augment the overall demand for biotechnology based chemicals in China. China is the largest consumer of biotechnology based chemicals market. The growing demand for citric acid especially from the food and beverage industry in China is expected to augment the overall demand for biotechnology based chemicals market. North America is expected to be the next largest consumer of biotechnology based chemicals owing to the growing consumer preference for natural products. The demand for biotechnology based chemicals is expected to grow rapidly owing to the presence of dominant animal feed and other end use industries in Europe.

Lysine is a crucial ingredient used in the animal feed for swine and poultry feeds. Thus, the growing demand for animal feed is expected to boost the overall demand for biotechnology based chemicals market. Rest of Asia Pacific is expected to experience rapid growth in the demand for biotechnology based chemicals owing to the growing pharmaceutical industry in the region. However, Rest of the World is expected to exhibit sluggish growth in the demand for biotechnology based chemicals in the next few years.

Kemin, BioAmber Inc. and Stora Enso are some of the major participants in the biotechnology based chemicals market. The companys present in the focus mainly towards research as they intend to introduce innovative products in the market.

This post was originally published on Market Research Sheets

Go here to see the original:
Biotechnology Based Chemicals Market Key Players, Industry Overview and Forecast Analysis by 2020 - Market Research Sheets

Read More...

The global liquid handling technology market is expected to reach US$ 5705.63 Mn in 2027 from US$ 3201.36 Mn in 2018 – P&T Community

December 28th, 2019 9:51 am

NEW YORK, Dec. 23, 2019 /PRNewswire/ --

The global liquid handling technology market is expected to reach US$ 5,705.63 Mn in 2027 from US$ 3,201.36 Mn in 2018. The market is estimated to grow with a CAGR of 6.7% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

The key factors that are driving the growth of liquid handling technology market are increasing drug discovery activities, growing biopharmaceutical industry and rising research and development expenses. Whereas, the market is expected to have slow growth due to the scarcity of skilled professionals during the forecast period.In the past few years, the biopharmaceutical industry has experienced exponential growth and is growing in the developing region at an extraordinary pace.The North American region owe highly advanced techniques that enable it to offers more of the biotechnology products in the market.

Regions such as Europe and the Asia Pacific have speeded up their investments and interest in the field of biotechnology, whereas regions such as South and Central America and the Middle East are developing their biotechnology industry significantly.Developed regions are consolidated with various market leaders and are experiencing a rising number of start-up biotechnology companies.The developing regions are collaborating with various market leaders and government entities to expand research and development activities in the biotechnology sector.

For instance, North American and European biotechnology sectors are heading towards the Asia Pacific region due to increased clinical activities. Since 2016, in the Asia Pacific, there are has been an increase in clinical activities from the biotech companies approximately by 26%.The biotechnology industry is also experiencing rising initiatives by the government and private bodies. For instance, in September 2017, the U.S.-Ukraine Foundation has launched a new biotechnology initiative to support the developments in the field of biotechnology, which resulted in the exertion to build new networking opportunities. Also, the U.S.-Ukraine Foundation has become a member of the Biotechnology Innovation Organization (BIO) and is the global leader of the trade association representing biotechnology companies, state biotechnology centers, academic institutions, and related organizations across the United States and more than 30 other nations.Thus, owing to the rise in biotechnology sector, increasing initiatives and growing clinical activities in the biotechnology industry are likely to increase the growth of the liquid handling technology market during the forecast period.The liquid handling technology market is segmented on the basis of product, type, application and end user.The market based on product segment is classified as automated workstations, small devices, consumables.

On the basis of type the market is classified as automated liquid handling, manual liquid handling, and semi-automated liquid handling. Based on the application segment market is divided into drug discovery & ADME-Tox Research, cancer and genomic research, bioprocessing/biotechnology. Based on end user the market is categorized as pharmaceutical and biotechnology companies, contract research organization, academic and research institutes

Read the full report: https://www.reportlinker.com/p05833605/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-liquid-handling-technology-market-is-expected-to-reach-us-5-705-63-mn-in-2027-from-us-3-201-36-mn-in-2018--300979003.html

SOURCE Reportlinker

Visit link:
The global liquid handling technology market is expected to reach US$ 5705.63 Mn in 2027 from US$ 3201.36 Mn in 2018 - P&T Community

Read More...

Puma Biotechnology, Inc. [PBYI] could give the highest percentage gains? Check Out this Analysis – The Dwinnex

December 28th, 2019 9:51 am

Puma Biotechnology, Inc. [PBYI] took an upward turn with a change of -1.36%, trading at the price of $8.73 during the trading session on . The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 528911 shares changed hands being bought and sold, while Puma Biotechnology, Inc. shares have an average trading volume of 1.76M shares for that time period. PBYI monthly volatility recorded 10.00%, in the meanwhile having share price volatility for the week set at 8.87%. PS value for PBYI stocks is 1.29 with PB recorded at 20.11.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $8.85.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on Thu 27 Feb (In 62 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total

What about valuation? This companys Enterprise Value to EBITDA is -3.71. The Enterprise Value to Sales for this firm is now 1.15, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 40.85M shares outstanding, amounting to a total market cap of $361.52M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -80.11% from its 52-week high, and it has moved up 39.46% from its 52-week low.

This stocks Beta value is currently 1.64, which indicates that it is 8.87% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 50.71. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

See the article here:
Puma Biotechnology, Inc. [PBYI] could give the highest percentage gains? Check Out this Analysis - The Dwinnex

Read More...

Pharmaceutical industry mounts opposition to states effort to curb drug costs – The Boston Globe

December 28th, 2019 9:51 am

As they finalize rules to control the cost of prescription drugs, state officials are meeting new resistance from the pharmaceutical industry.

Legislators and Governor Charlie Baker approved a change in law this summer that allows the administration to curb drug costs in the state Medicaid program, or MassHealth, by negotiating discounts directly with drug companies. If negotiations are unsuccessful, the administration can establish a target value for certain high-cost drugs, hold a public hearing, and refer the matter to the Health Policy Commission, a watchdog agency, for further review.

Then, the commission can demand more information from drug makers, but that information would remain out of public view.

Administration officials and the Health Policy Commission have been drafting detailed regulations to implement the law. But the Massachusetts Biotechnology Council, which represents biopharmaceutical companies, said the proposed regulations go too far.

We have strong concerns, said Zachary Stanley, a spokesman for MassBio. We think they are going beyond what the enabling law allows them to.

Stanley said drug makers are particularly worried that the administration wants to publicly post the target value of drugs. And theyre troubled by the amount and type of information that the Health Policy Commission plans to require from companies that are undergoing a review. For example, companies dont want to disclose the net prices that various insurance companies pay for their drugs or share their research and development costs.

The Pharmaceutical Research and Manufacturers of America, or PhRMA, raised similar issues, telling state officials it is deeply concerned about several aspects of the proposed regulations.

Baker first proposed a plan to tackle drug costs in MassHealth in January and drew immediate fire from pharmaceutical lobbyists. The proposal made for a lengthy debate at the State House. In late July, state lawmakers finally approved a version of Bakers plan but softened some of the language. At the time, MassBio called it a good compromise.

At this point, we want to make sure the law is enacted faithfully to what the Legislature intended, Stanley said.

Drug company lobbyists have argued that controls on prices could stifle innovation, particularly in the biotech hub of Massachusetts, where research labs represent an important piece of the economy.

But as drug costs continue rising for patients and for state governments policy makers have continued to target pharmaceutical companies.

In October, Baker filed a sweeping health care bill that would subject high-cost drugs to further state oversight and penalize companies that raise the price of any drug too sharply.

And in November, the Senate passed a bill that allows state officials to determine fair values for expensive medicines and to cap out-of-pocket costs for insulin.

House leaders are expected to introduce health care legislation in the new year.

Many organizations, including the consumer group Health Care For All, support stronger controls on prescription prices.

A coalition including Health Care For All, AARP Massachusetts, the Greater Boston Interfaith Organization, the Massachusetts Medical Society, and other groups told state officials this month that the proposed MassHealth regulations will save money for the state and taxpayers, while also protecting the 1.8 million residents who rely on the MassHealth program for their health care.

Some of the new MassHealth drug pricing provisions are already in effect. Since the law was enacted this summer, MassHealth officials said they already have negotiated discounts with five drug companies for 11 drugs, saving about $10 million.

Before discounts, the cost of drugs in MassHealth has grown to about $1.9 billion per year.

The administration and the Health Policy Commission plan to finalize their regulations over the next several weeks.

At a recent public hearing, Dr. John Christian Kryder, a board member of the Health Policy Commission, noted the difficult task for state officials.

The tradeoffs here are enormous if we dont get it right and create an environment where drug development does not occur, he said.

Priyanka Dayal McCluskey can be reached at priyanka. mccluskey@globe.com. Follow her on Twitter @priyanka_dayal.

Read the rest here:
Pharmaceutical industry mounts opposition to states effort to curb drug costs - The Boston Globe

Read More...

Is Odonate Therapeutics Inc (ODT) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

December 28th, 2019 9:51 am

Odonate Therapeutics Inc (ODT) is near the top in its industry group according to InvestorsObserver. ODT gets an overall rating of 46. That means it scores higher than 46 percent of stocks. Odonate Therapeutics Inc gets a 51 rank in the Biotechnology industry. Biotechnology is number 63 out of 148 industries.

Click Here to get the full Stock Score Report on Odonate Therapeutics Inc (ODT) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Odonate Therapeutics Inc (ODT) stock is down -3.69% while the S&P 500 has gained 0.03% as of 9:57 AM on Friday, Dec 27. ODT is down -$1.09 from the previous closing price of $29.53 on volume of 2,310 shares. Over the past year the S&P 500 is higher by 30.22% while ODT has gained 141.43%. ODT lost -$4.36 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

More here:
Is Odonate Therapeutics Inc (ODT) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX) – Yahoo Finance

December 28th, 2019 9:51 am

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory winners by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index returns are more affected by a few outlier stocks (i.e. the FAANG stocks dominating and driving S&P 500 Index's returns in recent years), more than 50% of the constituents of the Standard and Poors 500 Index underperform the benchmark. Hence, if you randomly pick a stock, there is more than 50% chance that you'd fail to beat the market. At the same time, the 20 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey generated an outperformance of more than 8 percentage points so far in 2019. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average. That's why we are going to go over recent hedge fund activity in Unity Biotechnology, Inc. (NASDAQ:UBX).

Unity Biotechnology, Inc. (NASDAQ:UBX) was in 4 hedge funds' portfolios at the end of September. UBX shareholders have witnessed a decrease in hedge fund interest recently. There were 5 hedge funds in our database with UBX positions at the end of the previous quarter. Our calculations also showed that UBX isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video below for Q2 rankings). Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

5 Most Popular Stocks Among Hedge Funds

Why do we pay any attention at all to hedge fund sentiment? Our research has shown that hedge funds' large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the Russell 2000 ETFs by 40 percentage points since May 2014 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that'll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.8% through November 21, 2019. That's why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Ken Griffin of Citadel Investment Group

We leave no stone unturned when looking for the next great investment idea. For example Discover is offering this insane cashback card, so we look into shorting the stock. One of the most bullish analysts in America just put his money where his mouth is. He says, "I'm investing more today than I did back in early 2009." So we check out his pitch. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We even check out this option genius' weekly trade ideas. This December, we recommended Adams Energy as a one-way bet based on an under-the-radar fund manager's investor letter and the stock already gained 20 percent. Keeping this in mind let's take a gander at the latest hedge fund action surrounding Unity Biotechnology, Inc. (NASDAQ:UBX).

Story continues

At the end of the third quarter, a total of 4 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -20% from the previous quarter. The graph below displays the number of hedge funds with bullish position in UBX over the last 17 quarters. With hedge funds' positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

Is UBX A Good Stock To Buy?

Of the funds tracked by Insider Monkey, Citadel Investment Group, managed by Ken Griffin, holds the biggest position in Unity Biotechnology, Inc. (NASDAQ:UBX). Citadel Investment Group has a $2.3 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which holds a $1.3 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Other peers that are bullish consist of Oleg Nodelman's EcoR1 Capital, Paul Marshall and Ian Wace's Marshall Wace and . In terms of the portfolio weights assigned to each position EcoR1 Capital allocated the biggest weight to Unity Biotechnology, Inc. (NASDAQ:UBX), around 0.04% of its 13F portfolio. Millennium Management is also relatively very bullish on the stock, dishing out 0.0021 percent of its 13F equity portfolio to UBX.

Seeing as Unity Biotechnology, Inc. (NASDAQ:UBX) has witnessed declining sentiment from the smart money, it's safe to say that there exists a select few money managers who sold off their full holdings in the third quarter. It's worth mentioning that Michael Castor's Sio Capital dumped the largest position of the "upper crust" of funds monitored by Insider Monkey, valued at close to $1 million in stock. Mike Vranos's fund, Ellington, also dropped its stock, about $0.1 million worth. These transactions are intriguing to say the least, as total hedge fund interest was cut by 1 funds in the third quarter.

Let's now review hedge fund activity in other stocks - not necessarily in the same industry as Unity Biotechnology, Inc. (NASDAQ:UBX) but similarly valued. These stocks are Compugen Ltd. (NASDAQ:CGEN), ShotSpotter, Inc. (NASDAQ:SSTI), Tsakos Energy Navigation Ltd. (NYSE:TNP), and ADMA Biologics Inc (NASDAQ:ADMA). This group of stocks' market values resemble UBX's market value.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position CGEN,4,7644,-1 SSTI,6,12594,0 TNP,7,27496,1 ADMA,11,105915,1 Average,7,38412,0.25 [/table]

View table hereif you experience formatting issues.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $38 million. That figure was $4 million in UBX's case. ADMA Biologics Inc (NASDAQ:ADMA) is the most popular stock in this table. On the other hand Compugen Ltd. (NASDAQ:CGEN) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Unity Biotechnology, Inc. (NASDAQ:UBX) is even less popular than CGEN. Hedge funds clearly dropped the ball on UBX as the stock delivered strong returns, though hedge funds' consensus picks still generated respectable returns. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. A small number of hedge funds were also right about betting on UBX as the stock returned 26.6% during the fourth quarter (through the end of November) and outperformed the market by an even larger margin.

Disclosure: None. This article was originally published at Insider Monkey.

Related Content

See the rest here:
Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX) - Yahoo Finance

Read More...

The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment – DocWire News

December 28th, 2019 9:50 am

A research team from the University of Houston has found a way to use the stem cells found in fat and guide it to become a pacemaker-like cell, according to a new study.

We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current, said study co-author Bradley McConnell, associate professor of pharmacology, in a press release

The team, publishing the study in the Journal of Molecular and Cellular Cardiology, worked on converting adipogenic mesenchymal stem cells, which reside within fat cells, into cardia progenitor cells. The ensuing cardiac progenitor cells can be programmed to aid heartbeats as a sinoatrial node (SAN), which is part of the electrical cardiac conduction system.

The researchers used what they called a standard screening strategy to test for reprogramming factors for converting human cardiac progenitor cells into pacemaker-like cells. According to their study results, the authors observed expressions of many pacemaker-specific genes, including CX30.2, KCNN4, HCN4, HCN3, HCN1, and SCN3b. The authors wrote that SHOX2, HCN2, and TBX5 (SHT5) combinations of transcription factors were much better candidate(s) in driving cardiac progenitor cells into pacemaker-like cells than other combinations and single transcription factors.

Results of this study show that the SHT5 combination of transcription factors can reprogram CPCs into Pacemaker-like cells, they wrote in their conclusion. SHT5 may be used as a potential stem cell therapy for sick sinus syndrome (SSS) and for other cardiac conduction diseases.

Original post:
The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News

Read More...

Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 – Bulletin Line

December 28th, 2019 9:50 am

The comprehensive report published by Persistence Market Research offers an in-depth intelligence related to the various factors that are likely to impact the demand, revenue generation, and sales of the Animal Stem Cell Therapy Market. In addition, the report singles out the different parameters that are expected to influence the overall dynamics of the Animal Stem Cell Therapy Market during the forecast period 2017 2025.

As per the findings of the presented study, the Animal Stem Cell Therapy Market is poised to surpass the value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% over the assessment period. The report includes a thorough analysis of the upstream raw materials, supply-demand ratio of the Animal Stem Cell Therapy in different regions, import-export trends and more to provide readers a fair understanding of the global market scenario.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

The report segregates the Animal Stem Cell Therapy Market into different segments to provide a detailed understanding of the various aspects of the market. The competitive analysis of the Animal Stem Cell Therapy Market includes valuable insights based on which, market players can formulate impactful growth strategies to enhance their presence in the Animal Stem Cell Therapy Market.

Key findings of the report:

The report aims to eliminate the following doubts related to the Animal Stem Cell Therapy Market:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

Reasons to buy from PMR

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

Read the original:
Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 - Bulletin Line

Read More...

Canterbury father and son’s invention will revolutionise medical treatment – Stuff.co.nz

December 28th, 2019 9:48 am

A typical father and son project might mean restoring a classic car or completing a home renovation, but this Christchurch pair have set their sights a little higher. LEE KENNY reports.

Phil and Anthony Butlerhave utilised cutting-edge technologyused in the hunt for the Higgs Boson to invent the world's first 3-D colour X-ray.

Phil is a professor at University of Canterbury and a Fellow of New Zealand Institute of Physics, while Anthony is a clinical radiologist and a professor at University of Otago.

Together they have created the MARS scanner, which will one day replace many of the functions of the X-ray, positron emission tomography (PET) scans and magnetic resonance imaging (MRI).

ALDEN WILLIAMS/STUFF

Phil and Anthony Butler work on an arm scanner at MARS' Christchurch laboratory.

READ MORE:* What will be the biggest scientific breakthrough of 2020?* Defence Force medic's bleeding edge invention wins Manawat's Innovate 2019* Where did the curiosity go?

The non-invasive technique will enable doctors to see colour images from inside the body, allowing them to make a more accurate diagnosis when treating everything from a broken bone to heart disease.

Phil, 72, first thought about the concept while he was atCERN (European Organization for Nuclear Research) in 2002.

Scientists working on the Large Hadron Collider used high-tech Medipix detectors to track particles and it was theorisedthey could also be used to detect X-ray photons.

Anthony joined CERN in 2005 and it was while the Butlerswere on a family holiday in Croatia that they decided to put the theory to the test.

Supplied

A 3-D image of Phil Butler's wrist taken by the MARS scanner in 2018.

They founded MARS Bioimaging in 2007 and today their 50-strong team consists of physicists, radiologists, mathematicians, biologists, engineers and computer scientists.

The company is part owned by University of Canterbury where it is based and has close ties to Otago Medical School.

Anthony, 44, explains the machine works by shining X-rays through the body and measuring the tissue composition before a computer reconstructs the information into a high-resolution 3-D colour image.

"The underlying process is often called spectral photon counting we measure the X-ray beam one photon at a time, which means we need to have very fast electronics to do this."

He says they have been looking at several medical applications for the scanners, across a range of clinical disciplines.

ALDEN WILLIAMS/STUFF

Professor Phil Butler is the chief executive of MARS Bioimaging but still takes a hands-on role.

"We've been working with orthopedic surgeons looking at fracture healing, cardiologists looking at the causes of heart disease and stroke, cancer specialists looking whether we can look at cell lines and the way they progress and we've looked at infectious diseases.

"That covers a large chunk of medicine and I expect we'll see [the scanners]hit the clinics at different times.

"It's going to be routine within a few years for a lot of point-of-care stuff."

The primary difference between the MARS scanner and other techniques is the level of detailed information it can record.

Anthony says the work is so cutting edge that components had to be built from scratch.

Dean Mouhtaropoulos

The MARS scanner was inspired by technology used at CERN, the World's Largest Particle Physics Laboratory.

"We did computer simulations to work out what we should be doing, then we had to come up with the designs, then manufacture it."

Dipanjan Pan, professor in chemical and biological engineering and radiology at University of Maryland Baltimore County, is an expert in nanomedicine and molecular imaging.

He collaborated with the MARS team for several years and says the3-D scanner has the potential to "dramatically change the ambiguity often found in black and white conventional CT imaging".

"Looking through MARS's proprietary photon counting CT 'magic lenses', you are visualising in colour the future of various biological processes as it merges with the present," he says.

"Their powerful reconstruction technique is astounding."

The technology has a range of uses from security and engineeringto physics and astronomy.

123rf

The traditional 2-D X-ray is good at showing solid objects like bones.

But the Butlers are focused on clinical applications and in July 2018 Phil became the first person to be scanned, with images generated of his wrist and ankle.

The next stage will be clinical trials next year when orthopaedic and rheumatology patients from Christchurch will bescanned.

Phil saysthe breakthrough is comparable to the first X-ray images in 1895 and the first low-resolution Computed Tomography (CT) in 1972.

"It's a major step. We went from 2-D to 3-D, now we're going from black and white to colour.

"The other thing that makes ours different from pretty much any other clinical system is we've got very high-resolution, basically 10 times the resolution of any other comparable technology."

Dr Diana Siew, associate director at MedTech Centre of Research Excellence at Auckland Bioengineering Institute, said the MARS X-ray scanner is a "game changer in medical diagnostics" because "it visualises what is happening in the body in a way that has not been achieved before".

"Different components of the body like fat, calcium, water and disease biomarkers show-up on the X-ray images in different colours, thus allowing a fuller and more accurate picture of a patient's condition," she says.

SUPPLIED

The new MRI scanner at Palmerston North Hospital had to be slotted through a hole in the wall when it was installed in April 2019.

"From a research perspective, this is exciting as it could underpin new understanding of disease onset and progression and be used to determine the efficacy of treatments.

"The MARS technology is a world's first and it is so exciting that it is happening in NZ."

As well as heralding a quantum leap in imaging capability, Anthony says the MARS technology will improve health treatment for Kiwis, as not everywhere has access to PET or MRI scanners.

"About half the people in rural New Zealand don't get appropriate cancer treatment, not because the country can't afford it but because the cancer centres are in large hospitals, the same is true for imaging," he says.

"If you are on the West Coast you cannot get a PET scan, you have to come over to Christchurch.

123RF

MRI scanners can record incredible detail but they are large and not widely available.

"So those access issues, we beat most of them because we use X-rays and they are very easy to have in a local practice, every dentist has got one."

Phil added: "One of the design goals for this system is to make it as easy to operate as a dentist's X-ray".

As well as the high cost of PET and MRI scanners, Anthony says there are other practicalities that make them less accessible.

"MRI requires rooms with big machines, you have to have liquid helium cooling it down, you can't put someone in with a pacemaker, certain vascular clips can't go in there [or] hip replacements," he says.

"With PET you have similar things, you have radioisotopes. In New Zealand we have one cyclotron in Wellington producing radioisotopes and they have to be flown around the country, so if it's a windy day in Wellington, no PET imaging can happen in the country."

Supplied

A 3-D image of Phil Butler's ankle, scanned in 2018.

MARS is operated from a secure area of University of Canterbury and as well as full-time staff, research is carried out by 15 PhD candidates.

Phil is in no doubt that a key component of the project's success is that it's based in Canterbury.

"If you look at the electronics or mechanical engineering skills of Christchurch, we can build anything," he says.

"We've got the skills to do it but the people also know each other, whereas if you go to a big city of several million, they can do it but they can't talk to their allied disciplines.

"That goes back to the farming industries, where people had to build their own machines and those skills of being able to build anything are all part of that."

Anthony agrees.

"If you go to really large research institutes they can be really skilled but they tend to have big silos. In New Zealand we tend not to operate that way.

Don Scott/Stuff

The Butlers, pictured here in 2010, examine coloured Iodine and Barium infused tissue.

"I think we're the sweet-spot in terms of size, where there's enough skill around that there's experts but we're not so big that we can't talk to each other."

Almost 15 years since the father and son team decided to embark on the research, they have made huge advances but there is still work to be done.

"If you look at where we were in 2006 or 2007 we were able to measure four colours but we had to do them one after the other, not simultaneously," Anthony says.

"We scanned the abdomen of a mouse, a pretty small object, and it [took] a day to image it and a month to do all the data reconstruction to get a picture to look at."

Day-to-day, Anthony is the company's chief medical officer and scientific lead.

Phil is the chief executive but, but according to Anthony, he still "does a lot of the technical work".

Working with family members can bring its challenges but Anthony says one of the advantages of partnering with his dad is the "innate trust" they have.

"It's actually a real pleasure," he says.

"I'm quite lucky, I didn't start working with him until I was in my early 30s, which meant I'd done all of my qualifications, established my own life.

"He had done many things himself and been pro-vice chancellor of the university and wanted to get more into practical applications so we founded this project together and that's been really nice.

"You're always going to have problems in any relationship but the fact that it's a family member gives you structure where you can actually work through problems and solve them and know that you're on the same team."

View post:
Canterbury father and son's invention will revolutionise medical treatment - Stuff.co.nz

Read More...

Page 774«..1020..773774775776..780790..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick